SCHEMBL6049210

SCHEMBL6049210

CN(c1ccc(Oc2ccc(OC(F)(F)F)cc2)c(C2CCCN2C(=O)O)c1)S(C)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD5 Q86SK9 1/20 0.38
▸ SERPINE1 P05121 1/20 0.37
▸ SLC6A4 P31645 5/20 0.37
▸ SLC6A2 P23975 4/20 0.37
▸ EPHX2 P34913 3/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ MMP9 P14780 3/20 0.37
▸ MMP2 P08253 2/20 0.37
▸ MMP1 P03956 2/20 0.37
▸ HTR2A P28223 1/20 0.36
▸ FFAR2 O15552 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ MMP3 P08254 1/20 0.35
▸ MMP7 P09237 1/20 0.35
▸ MMP8 P22894 1/20 0.35
▸ MMP13 P45452 1/20 0.35
▸ MMP14 P50281 1/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6049200 0.83 KIF11 (0.45) SCD5SLC6A4SLC6A2EPHX2SLC6A3
SCHEMBL7170392 0.79 EPHX2 (0.42) SCD5EPHX2MMP9MMP1HRH3
SCHEMBL6049191 0.77 GCK (0.43) SCD5SERPINE1EPHX2HRH3GCK
SCHEMBL6049192 0.77 GCK (0.43) SCD5SERPINE1EPHX2HRH3GCK
SCHEMBL6049201 0.77 TACR1 (0.40) SLC6A4SLC6A2SLC6A3HTR2ABRD4
SCHEMBL6049181 0.73 SLC6A4 (0.52) SLC6A4SLC6A2EPHX2SLC6A3MMP9
SCHEMBL6049231 0.71 EPHX2 (0.41) SCD5EPHX2BRD4
SCHEMBL2645563 0.69 GCK (0.44) SLC6A4MMP9MMP2GCK
SCHEMBL6049259 0.68 RAB9A (0.44) SERPINE1GCK
SCHEMBL6049260 0.68 RAB9A (0.44) SERPINE1GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 — — EP disclosed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US disclosed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US disclosed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs CRHR1, NR3C1, HTR6 SCD5 4261/4885SERPINE1 4814/4885SLC6A4 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback